ARS Pharmaceuticals Statistics
Share Statistics
ARS Pharmaceuticals has 98.21M
shares outstanding. The number of shares has increased by 1.26%
in one year.
| Shares Outstanding | 98.21M |
| Shares Change (YoY) | 1.26% |
| Shares Change (QoQ) | 0.96% |
| Owned by Institutions (%) | 73.45% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 46,199 |
| FTD / Avg. Volume | 2.82% |
Short Selling Information
The latest short interest is 16.73M, so 17.05% of the outstanding
shares have been sold short.
| Short Interest | 16.73M |
| Short % of Shares Out | 17.05% |
| Short % of Float | 31.79% |
| Short Ratio (days to cover) | 13.42 |
Valuation Ratios
The PE ratio is 127.87 and the forward
PE ratio is -24.48.
ARS Pharmaceuticals's PEG ratio is
-1.12.
| PE Ratio | 127.87 |
| Forward PE | -24.48 |
| PS Ratio | 11.47 |
| Forward PS | 2 |
| PB Ratio | 3.98 |
| P/FCF Ratio | 78.76 |
| PEG Ratio | -1.12 |
Financial Ratio HistoryEnterprise Valuation
ARS Pharmaceuticals has an Enterprise Value (EV) of 971.91M.
| EV / Sales | 10.9 |
| EV / EBITDA | -315.25 |
| EV / EBIT | 71.74 |
| EV / FCF | 74.85 |
Financial Position
The company has a current ratio of 14.26,
with a Debt / Equity ratio of 0.
| Current Ratio | 14.26 |
| Quick Ratio | 14.04 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 3.11% and Return on Invested Capital is -0.91%.
| Return on Equity | 3.11% |
| Return on Assets | 2.28% |
| Return on Invested Capital | -0.91% |
| Revenue Per Employee | $575,154.84 |
| Profits Per Employee | $51,600 |
| Employee Count | 155 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 0.19 |
Taxes
| Income Tax | 288K |
| Effective Tax Rate | 3.48% |
Stock Price Statistics
The stock price has increased by 54% in the
last 52 weeks. The beta is 0.94, so ARS Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.94 |
| 52-Week Price Change | 54% |
| 50-Day Moving Average | 12.96 |
| 200-Day Moving Average | 13.02 |
| Relative Strength Index (RSI) | 46.7 |
| Average Volume (20 Days) | 1,637,622 |
Income Statement
In the last 12 months, ARS Pharmaceuticals had revenue of 89.15M
and earned 8M
in profits. Earnings per share was 0.08.
| Revenue | 89.15M |
| Gross Profit | 88.17M |
| Operating Income | -3.08M |
| Net Income | 8M |
| EBITDA | -3.08M |
| EBIT | -3.08M |
| Earnings Per Share (EPS) | 0.08 |
Full Income StatementBalance Sheet
The company has 50.82M in cash and 42K in
debt, giving a net cash position of 50.77M.
| Cash & Cash Equivalents | 50.82M |
| Total Debt | 42K |
| Net Cash | 50.77M |
| Retained Earnings | -123.31M |
| Total Assets | 351.15M |
| Working Capital | 310.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 13.55M
and capital expenditures -563K, giving a free cash flow of 12.98M.
| Operating Cash Flow | 13.55M |
| Capital Expenditures | -563K |
| Free Cash Flow | 12.98M |
| FCF Per Share | 0.13 |
Full Cash Flow StatementMargins
Gross margin is 98.9%, with operating and profit margins of -3.46% and 8.97%.
| Gross Margin | 98.9% |
| Operating Margin | -3.46% |
| Pretax Margin | 9.29% |
| Profit Margin | 8.97% |
| EBITDA Margin | -3.46% |
| EBIT Margin | -3.46% |
| FCF Margin | 14.57% |
